Nā Māhele Lapaʻau

Nā Hana Lapaʻau i Hōʻike ʻia

Lapaʻau Virus Oncolytic: Lapaʻau Kanesa Holomua

CAR-T no Glioblastoma

ʻO Nusinersen Sodium Injection: Ka Manaʻolana no ka Atrophy Muscular Spinal

Lapaʻau CAR-T no ke Kanesa ʻōpū

$ʻO ka lāʻau lapaʻau CAR-T no ka Neuroblastoma Relapsed/Refractory$

ʻO ka lāʻau lapaʻau CAR-T no ka Neuroblastoma Relapsed/Refractory

CAR-T no ka Systemic Lupus Erythematosus (SLE)

ʻO ka maʻi ʻeha o ke kelepona ʻokiʻoki a me ka Thalassemia

Hāʻawi ka Innovative Gene Therapy i ka Manaʻolana Hou no nā maʻi Sickle Cell a me Thalassemia

FUCASO: ʻO ka lāʻau lapaʻau BCMA CAR-T kanaka piha me ka pono a me ka palekana i kūlike ʻole

Ke Hoʻohana ʻana i nā Pūnaewele NK: Ke Hoʻolaha nei i ka Lapaʻau Kanesa ma ʻō aku o nā Palena

0102030405

He ʻIkepili Holoʻokoʻa o ka Lapaʻau Leukemia Hou

ʻO ka CAR-T Therapy, pōkole no Chimeric Antigen Receptor T-Cell Immunotherapy, he ʻano hana lapaʻau gene holomua e pili ana i ka hoʻololi ʻana i nā pūnaewele T ponoʻī o ka mea maʻi e kuhikuhi a luku i nā pūnaewele kanesa. ʻAʻole e like me nā lāʻau lapaʻau kuʻuna, ua hana kūikawā ʻia ka CAR-T therapy no kēlā me kēia mea maʻi a koi ʻia ka hōʻiliʻili ʻana i nā pūnaewele T mai ke koko o ka mea maʻi ma mua o ka hoʻihoʻi ʻana iā lākou i loko o ke kino ma hope o ka ʻenekinia genetic.

Kāhea iā mā˚ou

Nā hōʻailona o CAR-T

● Leukemia lymphoblastic ʻāʻī o nā cell B

●ʻO ka myeloma lehulehu

●Leukemia lymphocytic mau loa

●ʻO ka lymphoma ʻaʻole Hodgkin

●ʻO ka lymphoma B-cell nui e hoʻolaha

●SLE (Lupus Erythematosus ʻōnaehana)

●ʻO ka maʻi ʻaʻai

●Nā maʻi autoimmune ʻē aʻe

Hana maikaʻi loa o ka hana lapaʻau CAR-T

Nā hōʻailona no CD19+20CAR-T: Nā maʻi me ka lymphoma B-cell non Hodgkin

Ka uku CR hoʻokahi mahina	Ka uku PR hoʻokahi mahina	Hoʻokahi mahina OR uku	CRS≥3	CRES≥3
71.95%（59/82）	25.6（21/82）	97.55（80/82）	12.19%（10/82）	0

Nā hōʻailona no CD19+22CAR-T: Ka mālama ʻana i nā maʻi leukemia B-lymphocytic acute i hoʻihoʻi ʻia mai ka CD19 a me ka refractory

Ka uku CR hoʻokahi mahina	Ka uku PR hoʻokahi mahina	Hoʻokahi mahina OR uku	CRS≥3	CRES≥3
92.1%（35/38）	7.9%（3/38）	100%（38/38）	15.79%（6/38）	0

Nā hōʻailona no BCMACAR-T: Ka mālama ʻana i ka myeloma maha relapsed a me ka refractory

Ka uku CR hoʻokahi mahina	Ka uku PR hoʻokahi mahina	Hoʻokahi mahina OR uku	CRS≥3	CRES≥3
72.41%（21/29）	27.59%（8/29）	100%（29/29）	6.9%（2/29）	0

Ko mākou mau pono

● Lapaʻau pilikinoHoʻopilikino ʻia kēlā me kēia lāʻau lapaʻau CAR-T i ka mea maʻi, e hōʻoiaʻiʻo ana i nā hopena lapaʻau i kuhikuhi pono ʻia a kūpono hoʻi.

● Nā Koho Hoʻolālā like ʻoleMe kahi ākea o nā antigens i manaʻo ʻia, me CD7, CD19, CD20, CD22, a me BCMA, hāʻawi kā mākou huahana CAR-T i ka versatility i kūlike ʻole i ka mālama ʻana i nā ʻano maʻi hematological like ʻole a me nā maʻi autoimmune.

● Ka Holomua Lapaʻau i Hōʻoia ʻiaUa hōʻike kā mākou mau lāʻau lapaʻau CAR-T i ka pono kūikawā ma nā hihia lapaʻau he nui, me nā helu kala ʻana kupaianaha a me nā ʻano palekana, e hoʻoikaika ana i ko mākou kūlana ma ke ʻano he alakaʻi i ka immunotherapy.

● Ka Pono Kūʻai KiʻekiʻeHāʻawi mākou i kahi lihi hoʻokūkū me nā ʻano hana maikaʻi loa ma ke kumukūʻai maʻalahi ke hoʻohālikelike ʻia me nā huahana CAR-T ʻē aʻe ma ka mākeke.

● ʻenehana ʻoi loaMe ka hoʻohana ʻana i nā holomua hou loa i ka ʻenekinia genetic, hōʻike kā mākou mau lāʻau lapaʻau CAR-T i ka wā e hiki mai ana o ka maʻi kanesa a me ka mālama ʻana i nā maʻi autoimmune.

● Kākoʻo Lapaʻau AkamaiHāʻawi kā mākou hui akamai o nā kauka lapaʻau a me nā mea noiʻi i ka mālama piha mai ke kūkākūkā mua ʻana a hiki i ka hoʻokele ʻana i ka lāʻau lapaʻau a me ka hahai ʻana.

Ua ʻike nui ʻia nā pūnaewele CAR-T i kēia manawa no ko lākou pono i nā poʻe maʻi i pane ʻole i nā lāʻau lapaʻau kuʻuna e like me ka chemotherapy a i ʻole ka hoʻoili ʻana o ka iwi iwi. Ua ʻae ke kaiāulu lapaʻau honua i ka hiki ke hoʻololi i ka CAR-T therapy i ka hoʻololi ʻana i nā hopena o ka mea maʻi.

Nā haʻawina a me nā hihia e pili ana i ka lāʻau lapaʻau CAR-T

1.CAR-T Therapy no ka Systemic Lupus Erythematosus: Ka Hana Kupaianaha ma ka Hihia Pediatric

Ua hōʻike ʻia kahi hihia hou ma ka Halemai Kulanui ʻo Erlangen i ka pono o ka lāʻau lapaʻau CAR-T i ka mālama ʻana i kahi kaikamahine 15 makahiki me ka systemic lupus erythematosus (SLE). Ma hope o kekahi mau lāʻau lapaʻau i hāʻule ʻole, ua loaʻa iā Uresa kēia lāʻau lapaʻau hou i Iune 2023. I ʻekolu pule ma hope o ka mālama ʻana, ua hoʻomaikaʻi nui ʻia kāna mau hōʻailona, e alakaʻi ana i ka hoʻōla piha ʻana a me ka hoʻihoʻi ʻana i ka hana o nā puʻupaʻa. ʻO kēia holomua ka hoʻohana mua ʻana o ka lāʻau lapaʻau CAR-T no nā maʻi autoimmune pediatric, e hōʻike ana i kona hiki ke hoʻokō i ke kala ʻana lōʻihi a hoʻololi i nā hopena o ka mea maʻi. Ke hana ʻia nei ka noiʻi hou aʻe e ʻimi i kāna mau noi ma nā kūlana like.

https://www.bioocus.com/news/breakthrough-in-pediatric-autoimmune-disease-car-t-cell-therapy-cures-lupus-patient/

2.CAR-T Therapy no ka Multiple Myeloma: Ua hoʻokō ʻia ke kala ʻana koʻikoʻi

ʻO Bjørn Simensen, he maʻi 67 makahiki mai Norewai mai, ua ʻike ʻo ia i kahi hoʻololi kupaianaha i kāna hakakā ʻana me ka myeloma multiple (IgG lambda, ISS-II) ma hope o ka loaʻa ʻana o ka lāʻau lapaʻau CAR-T cell. I ka wā i ʻike mua ʻia ai i ka makahiki 2017, ua hana ʻo ia i kekahi mau regimen chemotherapy, akā ua hoʻi hou i ka makahiki 2021. Ma hope o nā lāʻau lapaʻau kūpono ʻole, ua kuhikuhi ʻia ʻo ia i ka Halemai ʻo Lu Daopei i Pepeluali 2022, kahi i koho ʻia ai ʻo ia no ka lāʻau lapaʻau CAR-T. Ma hope o kahi regimen preconditioning, ua hoʻokomo ʻia kāna mau cell CAR-T. I ka lā 28, ua hōʻike nā hoʻokolohua hahai ʻana ʻaʻohe cell plasma ʻē i loko o kona iwi iwi, e hōʻailona ana i kahi holomua koʻikoʻi i kāna mālama ʻana.

https://www.bioocus.com/bj-rn-simensen-multiple-myeloma-igg-lambda-iss-ii-product/

3.CD7 CAR-T Therapy no ka Relapsed T-ALL a me LBL: Ka Pono a me nā Hopena Hoʻohiki

Hōʻike nā noiʻi hou i ka pono o ka lāʻau lapaʻau CD7 chimeric antigen receptor T-cell (CAR-T) i hui pū ʻia me ka lua o ka allogeneic hematopoietic stem cell transplantation (HSCT) no nā poʻe maʻi me ka relapsed T-cell acute lymphoblastic leukemia (T-ALL) a me ka lymphoblastic lymphoma (LBL). Ma ka Halemai ʻo Hebei Yanda Lu Daopei, ua pili ka noiʻi i 16 mau poʻe maʻi i loaʻa kahi 100% liʻiliʻi o ka maʻi koena (MRD)-negative complete remission ma hope o ka mālama ʻana. Me ka 75% o ka helu remission piha no nā lesions extramedullary a me hoʻokahi makahiki holoʻokoʻa o ke ola a me nā helu ola leukemia-free o 58.5% a me 51.4%, kēlā me kēia, hāʻawi kēia ʻano hana hou i ka manaʻolana hou no ke kala ʻana i ka wā lōʻihi i kēia mau maʻi ʻaʻai ʻino.

https://www.bioocus.com/news/promising-outcomes-of-cd7-car-t-therapy-combined-with-second-transplant-in-relapsed-t-all-lbl-patien/

4.CAR-T Therapy no ka B-Cell Acute Lymphoblastic Leukemia: Ka hopena i loaʻa ʻole ma mua

Ua hōʻike ʻia kahi noiʻi hou i ka pono kūikawā o ka chimeric antigen receptor-T cell therapy (CAR-T) i ka mālama ʻana i ka B-cell acute lymphoblastic leukemia (B-ALL). Ma ka laulima ʻana me BIOOCUS a me ka Halemai ʻo Lu Daopei, ua hōʻike ka noiʻi ua loaʻa i kahi helu nui o nā maʻi ke kala piha ʻana, e hoʻonoho ana i ka CAR-T therapy ma ke ʻano he koho lapaʻau alakaʻi no kēia leukemia koʻikoʻi. Hōʻike nā hopena hoʻohiki i ka hiki ke hoʻololi o ka CAR-T therapy i ka oncology, e hāʻawi ana i ka manaʻolana no nā maʻi a me nā ʻohana e kū nei iā B-ALL. I ka holomua ʻana o ka noiʻi, ua hoʻonohonoho ʻia ka CAR-T therapy e pāʻani i kahi kuleana koʻikoʻi i ka wā e hiki mai ana o ka mālama ʻana i ka maʻi kanesa.

https://www.bioocus.com/news/pioneering-car-t-therapy-in-b-cell-acute-lymphoblastic-leukemia-shows-unprecedented-efficacy/

Kaʻina Hana Lapaʻau CAR-T

1. Hōʻiliʻili Kelepona-T:

I ka wā mua, hōʻiliʻili nā kauka i nā pūnaewele T mai ke koko o ka mea maʻi me ka hoʻohana ʻana i kahi kaʻina hana i kapa ʻia ʻo leukapheresis. ʻO ka maʻamau, he 4 mau hola ka lōʻihi o kēia kaʻina hana, kahi e hoʻokaʻawale ai kahi mea hoʻokaʻawale koko i nā pūnaewele koko keʻokeʻo e pono ai a hoʻihoʻi i nā ʻāpana i koe i ke kino o ka mea maʻi.

2. Hoʻololi a me ka Hoʻonui ʻana o ka Genetic:

Hoʻouna ʻia nā pūnaewele T i hōʻiliʻili ʻia i kahi keʻena hoʻokolohua no ka hoʻololi ʻana i ka genetic. Ma kēia ʻanuʻu, hana ʻia nā pūnaewele T e kuhikuhi a luku i nā pūnaewele maʻi kanesa. He 2-3 mau pule ka lōʻihi o kēia kaʻina hana. I loko o kēia manawa, hoʻāla ʻia a hoʻonui ʻia nā pūnaewele T i loko o ka keʻena hoʻokolohua e hōʻoia i ko lākou pono e kūʻē i ka maʻi kanesa.

3. Hoʻokomo ʻana o ke kelepona:

Ma hope o ka mākaukau ʻana o nā pūnaewele T i hana ʻia, hoʻokomo hou ʻia lākou i loko o ke kino o ka mea maʻi ma o ka hoʻokomo ʻana i loko o ke kino. ʻO kēia kaʻina hana e hiki ai i nā pūnaewele pale i hoʻololi ʻia ke ʻike a hoʻopau pono i nā pūnaewele kanesa.

Hiki i nā maʻi ke loaʻa nā hopena ʻaoʻao i ka wā o ka mālama ʻana, ʻo ka mea maʻamau ka cytokine release syndrome (CRS), i hoʻokumu ʻia e ka pane ʻana o ka pale kino i ka wā o ka luku ʻana i nā cell cancer. ʻOiai hiki ke koʻikoʻi ka CRS, ua hōʻemi nui ka holomua ʻana i ka mālama olakino i kona mau pilikia.

ʻO ke kaʻina hana holoʻokoʻa, mai ka hōʻiliʻili ʻana i nā cell a hiki i ka hoʻokomo ʻana, maʻamau he 4-6 mau pule, ʻoiai ʻo ka lōʻihi pololei e pili ana i ke kūlana kikoʻī o ka mea maʻi.

Kākoʻo piha no nā maʻi o ka honua e hele ana i BIOOCUS no ka mālama ʻana iā CAR-T

Ma BIOOCUS, ua hoʻolaʻa ʻia mākou i ka hāʻawi ʻana i ka mālama kūikawā a me ke kākoʻo no nā poʻe maʻi o ka honua e ʻimi nei i ka lāʻau lapaʻau CAR-T. Uhi kā mākou lawelawe piha i kēlā me kēia ʻanuʻu o ka huakaʻi, mai nā hoʻomākaukau ma mua o ka huakaʻi a hiki i ka mālama ma hope o ka mālama ʻana.

1. Hoʻomākaukau Ma mua o ka Huakaʻi

Ma mua o ka hele ʻana i BIOOCUS, e hana ʻia kahi loiloi mua kikoʻī ma ko lākou hale lapaʻau kūloko. Hoʻokomo pū kēia i kahi loiloi piha o ka mōʻaukala olakino, nā hoʻokolohua kino, a me nā hoʻokolohua pili e like me ka hana koko, nā haʻawina kiʻi, a me nā nānā kikoʻī i ke ʻano maʻi kanesa e mālama ʻia nei (e like me ka leukemia, lymphoma, a i ʻole nā maʻi kanesa koko ʻē aʻe). Hoʻomaopopo mākou e hoʻouna ʻia nā moʻolelo olakino āpau, me nā lāʻau lapaʻau mua, nā hopena hoʻāʻo, a me nā hōʻoia hōʻoia, i kā mākou hui no ka loiloi a me ka hoʻomākaukau ʻana.

2. Huakaʻi a me ka Hoʻokipa ʻana i ka Halemai

Kōkua mākou i nā ʻano āpau o ka huakaʻi, me ka hoʻonohonoho ʻana i kahi noho a me nā hoʻopaʻa ʻana i ka haukapila ma BIOOCUS International Medical Center. I ka hōʻea ʻana, alakaʻi ʻia nā mea maʻi ma ke kaʻina hana komo, e hōʻoiaʻiʻo ana i kahi neʻe maʻalahi i loko o ke kaiapuni mālama.

3. Kaʻina Hana Lapaʻau

Ma ke komo ʻana, e hana ʻia nā maʻi i kekahi mau hoʻokolohua mua, me nā loiloi e hōʻoia i ke kūpono no ka lāʻau lapaʻau CAR-T. E pili ana kēia i ka loiloi ʻana i ke kūlana o ka maʻi kanesa a me ke olakino holoʻokoʻa, a me ka hōʻiliʻili koko no ka unuhi ʻana i nā cell T. A laila hoʻouna ʻia nā cell T i hōʻiliʻili ʻia i kā mākou lab i hōʻoia ʻia e GMP no ka hoʻololi ʻana i ka genetic. Hiki i kēia kaʻina hana ke hala ma kahi o 2-3 mau pule.

4.Cell Infusion a me ka mālama ma hope o ka mālama ʻana

Ke mākaukau nā pūnaewele CAR-T i hoʻololi ʻia, e hoʻi nā mea maʻi i ko mākou haukapila no ke kaʻina hana hoʻokomo. He lāʻau lapaʻau hoʻokahi manawa kēia kahi e lawelawe ʻia ai nā pūnaewele T i hana ʻia ma ke ʻano intravenous. Ma hope o ka hoʻokomo ʻana, e noho nā mea maʻi ma lalo o ka nānā pono ʻana no kekahi mau lā e nānā no nā hopena ʻaoʻao, e like me ka cytokine release syndrome, he hopena paha ia i ka lāʻau. Hāʻawi kā mākou hui lapaʻau i ke kākoʻo mau a me ka nānā ʻana i kēia wā koʻikoʻi.

Ma hope o ka hoʻokuʻu ʻia ʻana, hoʻonohonoho ʻo BIOOCUS i nā kipa hahai maʻamau, me nā hoʻokolohua hoʻokolohua a me nā haʻawina kiʻi, e nānā i ka pono o ka lāʻau lapaʻau a hahai i ka hoʻōla ʻana o ka mea maʻi. E nānā pono ʻia nā mea maʻi no nā hopena lohi o ka lāʻau lapaʻau, a e hoʻomau kā mākou hui i ka launa pū ʻana e hāʻawi i ke alakaʻi a me ke kākoʻo mau.

Ma BIOOCUS, ke kau nei mākou i ka manaʻo nui i ke olakino, ka palekana, a me ka ʻoluʻolu o kā mākou mau maʻi honua. ʻO kā mākou pahuhopu ka hāʻawi ʻana i ka mālama piha a me ka hōʻoia ʻana i kahi ʻike kākoʻo a maʻalahi hoʻi ma o ka huakaʻi lapaʻau CAR-T.

No ka ʻike hou aku e pili ana i kā mākou mau lawelawe a pehea e hiki ai iā mākou ke kōkua me kāu lapaʻau, e ʻoluʻolu e kelepona pololei mai iā mākou.

wehewehe2

Submit An Free Inquiry

Our medical team will make an evaluation for you, based on the information you provided. This procedure is free of charge.